Literature DB >> 18256188

Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.

Xiaoqun Zhang1, Per E Andren, Paul Greengard, Per Svenningsson.   

Abstract

Parkinson's disease (PD) is characterized by a progressive degeneration of substantia nigra dopaminergic neurons projecting to the striatum. Restoration of dopamine transmission by L-DOPA relieves symptoms of PD but causes prominent side effects. There is a strong serotonin innervation of the striatum by serotonergic neurons that remains relatively preserved in PD. The study of this innervation has been largely neglected. Here, we demonstrate that chronic L-DOPA administration to 6-OHDA-lesioned rodents increases, via D1 receptors, the levels of the 5-HT1B receptor and its adaptor protein, p11, in dopamine-denervated striatonigral neurons. Using unilaterally 6-OHDA-lesioned p11 WT and KO mice, it was found that administration of a selective 5-HT1B receptor agonist, CP94253, inhibited L-DOPA-induced rotational behavior and abnormal involuntary movements in a p11-dependent manner. These data reveal an L-DOPA-induced negative-feedback mechanism, whereby the serotonin system may influence the symptomatology of Parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256188      PMCID: PMC2538893          DOI: 10.1073/pnas.0711839105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Levodopa and the progression of Parkinson's disease.

Authors:  Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

2.  Differential actions of serotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro.

Authors:  I M Stanford; M G Lacey
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

3.  ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.

Authors:  Nancy Pavón; Ana B Martín; Ainhoa Mendialdua; Rosario Moratalla
Journal:  Biol Psychiatry       Date:  2005-09-01       Impact factor: 13.382

4.  Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.

Authors:  Flora Mela; Matteo Marti; Andrzej Dekundy; Wojciech Danysz; Michele Morari; M Angela Cenci
Journal:  J Neurochem       Date:  2007-01-15       Impact factor: 5.372

5.  Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

Authors:  Céline Guigoni; Evelyne Doudnikoff; Qin Li; Bertrand Bloch; Erwan Bezard
Journal:  Neurobiol Dis       Date:  2007-02-09       Impact factor: 5.996

6.  Alterations in 5-HT1B receptor function by p11 in depression-like states.

Authors:  Per Svenningsson; Karima Chergui; Ilan Rachleff; Marc Flajolet; Xiaoqun Zhang; Malika El Yacoubi; Jean-Marie Vaugeois; George G Nomikos; Paul Greengard
Journal:  Science       Date:  2006-01-06       Impact factor: 47.728

7.  Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

Authors:  Incarnation Aubert; Céline Guigoni; Kerstin Håkansson; Qin Li; Sandra Dovero; Nicole Barthe; Bernard H Bioulac; Christian E Gross; Gilberto Fisone; Bertrand Bloch; Erwan Bezard
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

8.  A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

Authors:  Tom H Johnston; Joohyung Lee; Jordi Gomez-Ramirez; Susan H Fox; Jonathan M Brotchie
Journal:  Exp Neurol       Date:  2005-02       Impact factor: 5.330

9.  L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.

Authors:  M A Cenci; C S Lee; A Björklund
Journal:  Eur J Neurosci       Date:  1998-08       Impact factor: 3.386

10.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15
View more
  36 in total

1.  p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.

Authors:  Nicoletta Schintu; Xiaoqun Zhang; Alexandra Alvarsson; Roberta Marongiu; Michael G Kaplitt; Paul Greengard; Per Svenningsson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

2.  Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT.

Authors:  Martin Schain; Miklós Tóth; Zsolt Cselényi; Ryosuke Arakawa; Christer Halldin; Lars Farde; Andrea Varrone
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-18       Impact factor: 9.236

3.  Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Seunghyi Kook; Lilia Zurkovsky; Kevin N Dalby; Eugenia V Gurevich
Journal:  Exp Neurol       Date:  2015-02-14       Impact factor: 5.330

4.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

5.  CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.

Authors:  Mona Nouhi; Xiaoqun Zhang; Ning Yao; Karima Chergui
Journal:  CNS Neurosci Ther       Date:  2017-12-11       Impact factor: 5.243

Review 6.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

Review 7.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

8.  Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease.

Authors:  Holly Green; Xiaoqun Zhang; Katarina Tiklova; Nikolaos Volakakis; Lovisa Brodin; Louise Berg; Paul Greengard; Thomas Perlmann; Per Svenningsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

9.  Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: implication for Parkinson's disease.

Authors:  X Zhang; Z-J Feng; K Chergui
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

10.  Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats.

Authors:  Shetty Ravi Dyavar; Lisa F Potts; Goichi Beck; Bhagya Laxmi Dyavar Shetty; Benton Lawson; Anthony T Podany; Courtney V Fletcher; Rama Rao Amara; Stella M Papa
Journal:  Genes Brain Behav       Date:  2020-09-11       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.